BioLineRx (NASDAQ:BLRX) Announces Earnings Results, Misses Estimates By $0.01 EPS

BioLineRx (NASDAQ:BLRX – Get Rating) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), Zacks reports. During the same quarter last year, the business earned ($0.10) earnings per share.

BioLineRx Stock Down 5.9 %

BioLineRx stock traded down $0.09 during midday trading on Friday, hitting $1.46. 459,943 shares of the stock were exchanged, compared to its average volume of 406,691. BioLineRx has a 52-week low of $0.55 and a 52-week high of $1.98. The stock has a market capitalization of $89.78 million, a price-to-earnings ratio of -2.65 and a beta of 1.89. The business’s 50-day moving average price is $1.12 and its 200-day moving average price is $0.81. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. purchased a new position in BioLineRx in the first quarter valued at about $88,000. Renaissance Technologies LLC boosted its stake in BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 189,678 shares during the last quarter. LPL Financial LLC boosted its stake in BioLineRx by 152.7% in the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares during the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new position in BioLineRx in the first quarter valued at about $178,000. 18.15% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on BLRX shares. StockNews.com started coverage on shares of BioLineRx in a research note on Thursday, May 18th. They set a “sell” rating for the company. HC Wainwright reissued a “buy” rating on shares of BioLineRx in a research note on Wednesday, March 22nd.

About BioLineRx

(Get Rating)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors.